Pharmacokinetic and safety of a novel pleiotropic compound in C57BL/6J mice with potential therapeutic interest in Alzheimer’s disease
Caroline Lahogue, Stacy Largilliere, Gerald Nee, Alice Wang, Stephanie Lagadu, Thomas Culerier, Marc Since, Raphael Delepee, Jean-Marie Billard, Aurelie Malzert-Freon, Anne-Claire Groo, Christophe Rochais, Patrick Dallemagne, Thomas Freret, Michel Boulouard · FENS Forum 2024
Several therapeutic targets have been identified to counteract the cognitive decline of Alzheimer's disease (AD). One of the recent approaches, which takes account the multifactorial origin of AD, is pleiotropic drugs. Multi-targeted directed ligands are designed to target different molecular causes involved in the pathogenesis of AD. A novel compound, acting as a prodrug and able of both selectively inhibiting butyrylcholinesterase and secondarily interacting with serotonin subtype 4 receptor, has therefore been developed. The first step of the project was to assess pharmacological screening
ePoster · Neuroscience